Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cidara Therapeutics, Inc.

https://www.cidara.com/

Latest From Cidara Therapeutics, Inc.

Finance Watch: Three Newly Public Companies Face Mixed Reception In Early Trading

Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.

Financing Business Strategies

Cidara Aims For Treatment, Prophylaxis Claims For Novel Antifungal

Biotech says rezafungin should best existing echinocandin agents in treatment of Candida pathogen infections, while also offering needed prophylaxis improvements for leukemia and lymphoma patients.

Research & Development Business Strategies

Cidara, Janssen To Tackle Flu With Antiviral Conjugates

Cidara partners its antiviral conjugate platform for seasonal and pandemic influenza with Janssen, which also gets option rights to an AVC candidate for respiratory syncytial virus.

Deals Business Strategies

Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease

Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.

Scrip Asks Artificial Intelligence
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register